Bristol-Myers Squibb Company (BMY)
Bristol-Myers Squibb: Sell Now, Buy Later (Rating Downgrade)
Bristol-Myers Squibb stock surged after surprisingly good Q2 2024 results, but it's unlikely that the rise can be sustained for now. The company's upgraded guidance is too small to improve prospects for H2 2024, with lower revenue growth and earnings contraction ahead. BMY's steep price rise over the past month and its elevated valuations compared to peers make it unattractive too.
Bristol-Myers Squibb: A Potential Comeback In Healthcare
On July 26, Bristol-Myers Squibb pleasantly shocked Wall Street with its financial results for the second quarter of 2024. Thanks to strong sales of the company's oncology franchise, it raised its full-year 2024 guidance. Sales of Breyanzi, a CAR T-cell therapy, were $153 million in the second quarter of 2024, up 53% year-on-year.
Best Dividend Stocks Yielding Over 5% to Buy Now
24/7 Wall St. Insights With inflation starting to be tamed, dividend stocks will be in big demand as rates drop.
Bristol Myers Squibb (BMY) Crossed Above the 200-Day Moving Average: What That Means for Investors
From a technical perspective, Bristol Myers Squibb (BMY) is looking like an interesting pick, as it just reached a key level of support. BMY recently overtook the 200-day moving average, and this suggests a long-term bullish trend.
Bargain-Hunters Paradise: 7 Value Stocks That Are Too Cheap to Ignore
The market consistently offers opportunities in value stocks for bargain hunters willing to do the work and take risks. Most of the work is done here for you as I have identified value stocks that are cheaply priced.
Dividend Harvesting Portfolio Week 178: $17,800 Allocated, $1,612.87 In Projected Dividends
Alphabet and Tesla had negative reactions to Q2 earnings reports. Economic data showed PCE increased 0.1% MoM, while consumer confidence declined for the 4th consecutive month. The Dividend Harvesting Portfolio had another positive week, reaching new highs in dividend income.
2 High Conviction Buys Yielding 5-8%
Buying high-growth stocks may not always lead to long-term returns due to high share prices and low dividend yields, lessening the impact of dividend reinvestment. Bristol-Myers Squibb offers strong revenue growth, a promising drug pipeline, and a 4.9% dividend yield with potential for long-term growth. Ladder Capital provides a well-diversified loan portfolio, strong earnings, and a substantial 7.5% dividend yield, making it an attractive option for income and total returns.
Should You Pick Bristol Myers Squibb Stock At $50 After A Solid Q2 Beat?
Bristol Myers Squibb (NYSE: BMY) recently reported its Q2 results, with revenues and earnings exceeding our estimates. The company reported revenue of $12.2 billion and adjusted earnings of $2.07 per share, compared to our estimates of $11.6 billion in sales and $1.65 profit per share.
The Top 3 Healthcare Stocks to Buy Now: Summer 2024
One of the most pertinent drivers of the stock market that is often not considered by many investors is the demographic trajectory of the U.S. Currently, the U.S. population is older than ever before in history. For example, between 1980 and 2022, the median age of the American population increased from 30.0 to 38.9.
BMY vs. VRTX: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Bristol Myers Squibb (BMY) and Vertex Pharmaceuticals (VRTX). But which of these two companies is the best option for those looking for undervalued stocks?
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers (BMY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Is Bristol Myers Squibb a Good Dividend Stock to Buy Now?
Bristol Myers Squibb lowered its earnings outlook earlier this year to account for recent acquisitions. One of Bristol Myers Squibb's top-selling drugs, Revlimid, has already lost patent-protected market exclusivity.
